Thrombin-inhibiting perfluorocarbon nanoparticles provide a novel strategy for the treatment and magnetic resonance imaging of acute thrombosis. - Wikidata - awgldk - TriplyDB

Thrombin-inhibiting perfluorocarbon nanoparticles provide a novel strategy for the treatment and magnetic resonance imaging of acute thrombosis.

Thrombin-inhibiting perfluorocarbon nanoparticles provide a novel strategy for the treatment and magnetic resonance imaging of acute thrombosis.

http://www.wikidata.org/entity/Q42168945

about

Molecular imaging of atherosclerosis with nanoparticle-based fluorinated MRI contrast agents Quantifying progression and regression of thrombotic risk in experimental atherosclerosis Recent Advances in (19)Fluorine Magnetic Resonance Imaging with Perfluorocarbon Emulsions.Perfluorocarbon nanoparticles for physiological and molecular imaging and therapy Perspectives and opportunities for nanomedicine in the management of atherosclerosis.Acceleration of tissue plasminogen activator-mediated thrombolysis by magnetically powered nanomotors.Intracellular pH measurements using perfluorocarbon nanoemulsions Thrombin-inhibiting nanoparticles rapidly constitute versatile and detectable anticlotting surfaces.Antithrombin nanoparticles improve kidney reperfusion and protect kidney function after ischemia-reperfusion injury.Nanomedical Theranostics in Cardiovascular Disease.Inhibition of Thrombin With PPACK-Nanoparticles Restores Disrupted Endothelial Barriers and Attenuates Thrombotic Risk in Experimental Atherosclerosis Thrombosis: Novel nanomedical concepts of diagnosis and treatment BLOOD TRIGGERED RAPID RELEASE POROUS NANOCAPSULES.Two-color fluorescent (near-infrared and visible) triphasic perfluorocarbon nanoemuslions.Vascular Inflammation: A Novel Access Route for Nanomedicine Thrombin-targeted liposomes establish a sustained localized anticlotting barrier against acute thrombosis.Advances in nanotechnology for the management of coronary artery disease.Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines.Theranostic nanoparticles for cancer and cardiovascular applications.Engineered nanoparticles: thrombotic events in cancer.Modifications of natural peptides for nanoparticle and drug design.The Future of Nanoparticle-Directed Venous Therapy.The melding of nanomedicine in thrombosis imaging and treatment: a review.Nanomedicine applied to cardiovascular diseases: latest developments.Nanomedicine in coronary artery disease.Antithrombin nanoparticles inhibit stent thrombosis in ex vivo static and flow models.An unmet clinical need: The history of thrombus imaging.Quantification of vascular damage in acute kidney injury with fluorine magnetic resonance imaging and spectroscopy.Recent Advances in Treatment of Coronary Artery Disease: Role of Science and Technology.Thrombin-Inhibiting Anticoagulant Liposomes: Development and Characterization.Antithrombin Perfluorocarbon Nanoparticles Improve Renal Allograft Function in a Murine Deceased Criteria Donor Model Anti-JNK2 peptide-siRNA nanostructures improve plaque endothelium and reduce thrombotic risk in atherosclerotic mice

P2860

Q27027613-38A69034-C57D-47BF-80EE-ABA33EFC8698 Q27318779-56EB19BF-EBAF-4E0C-B634-4C74B2147816 Q30385272-3AE3E62F-9516-4FC2-B9E1-5D9A36DCFB89 Q30426880-D9D37CA9-B6F5-4FBC-A1C0-3A8E16F6D2BA Q30455490-7D88F25F-F08D-486C-9DDB-8CE436FBDD9B Q30586518-DF624A3D-B55E-4E0E-B573-A978580B443C Q34399286-03711146-F3E9-45A8-8D7B-478C8712BE82 Q34545939-1E2B9202-DAFB-4BBE-9B10-B0CA0283B4DB Q35274033-3FD81DB5-3091-4D50-AC3D-5213DC1A95B7 Q35681183-5D5273C7-31A9-4773-8F27-885CE804597A Q35894640-44961EEB-B10B-4F02-8B88-812CD4F91899 Q35996696-3DFA9502-206A-4C91-BDCD-E637777312BF Q36768912-D25B8018-DE69-47A5-97A4-C6304E47B12B Q37064676-F312F597-B922-44F1-ACC5-AB145B7B54D8 Q37397963-528004BC-6E58-4A08-86B5-EBFDFBE34FC6 Q37624589-73688DDE-FE12-447D-A1AE-F1A493B83799 Q38067933-6A053CF5-5143-4289-85CD-BBFCDC9FEB8C Q38112504-2B351988-D45E-46FD-9186-C8905EAB0A41 Q38193333-288F5B25-51A3-43C8-8B2C-5CCCD3C6161E Q38262939-6E7E8280-01B1-426E-BD6B-27DE8870FAAD Q38369494-3FA54DB8-52F0-4E89-9F5E-101AB5E54731 Q38749932-7C655318-DAD5-4108-B737-B6AF306D6087 Q38776819-6D0AB4A8-CFCB-435E-AAC0-55C6AD8A93D8 Q39136197-4700F071-FEB3-4C14-B0B2-B3177757DE42 Q39276023-09D6227B-C843-49D0-AE93-17BD21205292 Q42877162-BA82FE47-9484-42C6-B996-401A45ACABC8 Q47177380-797149D7-DD97-48DA-9A92-3B0848DB06F7 Q47338726-52D1CAAE-D67A-467D-96C1-F6D13138FECC Q47642528-162068D2-BB8D-4D9D-970B-BECA33E9563D Q48089546-69E91547-CBF2-408F-A86F-1A27C9CA19C9 Q58726802-FF6667B4-ECF5-4926-BFFE-61608E60C6E3 Q58761484-1570E51B-559A-4261-B10A-048F8FAC2898

P2860

Thrombin-inhibiting perfluorocarbon nanoparticles provide a novel strategy for the treatment and magnetic resonance imaging of acute thrombosis.

http://www.wikidata.org/entity/Q42168945

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Thrombin-inhibiting perfluoroc ...... e imaging of acute thrombosis.

@en

Thrombin-inhibiting perfluoroc ...... e imaging of acute thrombosis.

@nl

type

label

Thrombin-inhibiting perfluoroc ...... e imaging of acute thrombosis.

@en

Thrombin-inhibiting perfluoroc ...... e imaging of acute thrombosis.

@nl

prefLabel

Thrombin-inhibiting perfluoroc ...... e imaging of acute thrombosis.

@en

Thrombin-inhibiting perfluoroc ...... e imaging of acute thrombosis.

@nl

P1433

Q42168945-DF3A8E60-FA62-4285-B861-BABD5A95209D

P1476

Q42168945-CF67ED74-FAD3-475D-9734-F7097F9E24B3

P2093

Q42168945-3ADD5FB2-A385-493B-AECB-58430A2D1A66

Q42168945-4C8E50E7-59B5-4F4F-8E99-AF9DEB4EA23D

Q42168945-6D5C4719-47ED-4307-BE9A-58508DEB0870

Q42168945-EB1AEC5C-D54C-4D9F-AB06-AA39905C2722

Q42168945-FE9D2878-8753-4383-B3B2-BBED390359FF

P2860

Q42168945-08EF4BFF-DE5D-4E1F-B34B-CA9C5032C792

Q42168945-298668BB-FB89-4082-A599-39E3865164F5

Q42168945-2C38A40F-E6E1-437B-B1A4-6A1996AFB398

Q42168945-3F81D8FE-16C0-44CC-9303-D9BA08FA2182

Q42168945-4B08A740-6167-4033-A2F8-BC642875A45B

Q42168945-556AD334-21D1-4D0E-AE80-2CD38554F65A

Q42168945-5CD5F3D8-C8BD-42E9-9563-6115A457DEFB

Q42168945-67012EF7-7F25-4E29-BC3E-0869B6067C77

Q42168945-708A1418-30DC-4DF5-AB07-EE89320159C1

Q42168945-88A3A64A-BE13-4579-A26F-AF27F4821793

P304

Q42168945-CF317149-7A8A-46FB-87F1-84F0618C8E21

P31

Q42168945-151EE8E7-8ADA-4060-BC21-E33F48810073

P356

Q42168945-D78619DB-305E-4AA1-ACB4-60B645B5CDC1

P433

Q42168945-DFB708E5-D83C-4E73-BB9F-B2A0C8207701

P478

Q42168945-606D6E80-4C5F-4B3D-8E31-FB2C65476852

P577

Q42168945-960163B4-02DF-4DBC-8D38-1CFE8922F162

P698

Q42168945-F2E14947-0E47-4495-94D4-1D431069D789

P921

Q42168945-18BF731A-3B77-4485-8BE9-F987811533A1

Q42168945-3C8CD6F3-6655-4BE2-890D-389EE5219FF9

Q42168945-57862181-449A-4B90-963C-EDC8B80C834D

P932

Q42168945-40628F33-6AAE-40D3-B17B-6A679A64C40A

P356

J.1538-7836.2011.04339.X

P1433

Journal of Thrombosis and Haemostasis

P1476

Thrombin-inhibiting perfluoroc ...... e imaging of acute thrombosis.

@en

P2093

D Tollefsen

http://www.w3.org/2001/XMLSchema#string

G Lanza

http://www.w3.org/2001/XMLSchema#string

J Myerson

http://www.w3.org/2001/XMLSchema#string

L He

http://www.w3.org/2001/XMLSchema#string

S Wickline

http://www.w3.org/2001/XMLSchema#string

P2860

The refined 1.9-Å X-ray crystal structure of d-Phe-Pro-Arg chloromethylketone-inhibited human α-thrombin: Structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships

Evidence for functionally active protease-activated receptor-4 (PAR-4) in human vascular smooth muscle cells

Thrombin signalling and protease-activated receptors

The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Murine models of vascular thrombosis (Eitzman series).

Antithrombotic activity of dermatan sulfate in heparin cofactor II-deficient mice.

An overview of the structure and function of thrombin.

Mechanisms of thrombus formation

Progress in the design of low molecular weight thrombin inhibitors.

Molecular imaging by MRI.

P304

1292-1300

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1538-7836.2011.04339.X

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2011-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21605330

http://www.w3.org/2001/XMLSchema#string

P921

magnetic nanoparticles

P932

3686484

http://www.w3.org/2001/XMLSchema#string